Diabetes

Advance of disease driven by high BMI, with social determinants of health playing a role

Endocrinologists urged to pay attention to COORDINATE trial

Once-weekly CagriSema reduced body weight more than either agent alone

Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

More positive results in CLEAR Outcomes sub-analysis

Superior to once-a-day insulin glargine U100 and degludec

Daily orforglipron also lowered HbA1c in type 2 diabetes

Phase IIb ENLIVEN trial saw success with various doses of pegozafermin

Health news and commentary from around the Web gathered by MedPage Today staff

Researcher warns of "alarm fatigue" if thresholds aren't optimized to patient

Study findings highlight the importance of prioritizing eye care, diabetic retinopathy screening

Indirect medical expenses, diabetic alert dogs among top fundraising requests

New study finds marked risk reduction tied to drugs' urate-lowering effect